BWBrandon S. Walker

Brandon S. Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brandon S. Walker has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A longitudinal analysis of incidence of hypertension and blood pressure measurements by age of migration among older Hispanic men and women

    by Brandon S. Walker, Norman J Waitzman, Evan V. Goldstein, Megan E. Vanneman, Alan Taylor Kelley, Fernando A. Wilson

    Objective: To conduct a longitudinal analysis of incidence of self-reported hypertension and blood pressure measurements among foreign-born Hispanics by age of migration, compared to US-born populations. Methods: The sample was drawn from 2002-2018 of the Health and Retirement Study and included 22,909 individuals. Subsets of this sample were used to conduct a longitudinal analysis of the incidence of hypertension and mean blood pressure measurements. Results: Foreign-born Hispanic women migrating at age 40 and older had a greater incidence of hypertension and a greater increase in systolic blood pressure as they aged compared to US-born Whites. Discussion: In contrast to the Hispanic Paradox that suggests better health among Hispanic immigrants despite lower socioeconomic status, this was not observed among older Hispanic immigrants for hypertension. Furthermore, older Hispanic women who migrated later in life had a greater incidence of hypertension and greater increases in systolic blood pressure as they aged compared to US-born White women.

  • The Fading of Protective Roots: A Multivariate Analysis of the Risk of Hypertension among Hispanics by Nativity

    by Brandon S. Walker, Norman J. Waitzman

    Objective: To examine the effects of Hispanic nativity on the risk and severity of hypertension relative to US-born non-Hispanic whites. Methods: The analytic sample ( n = 34,007) was comprised of cross-sectional data drawn from twenty years of the National Health and Nutrition Examination Survey, 1999–2018. Results: Foreign-born Hispanics aged 65 years and older had a greater risk of severe hypertension compared to non-Hispanic Whites. When examined by length of residency in the US, elderly foreign-born Hispanics with less than 10 years of residency were at greater risk of hypertension and severe hypertension, while those with 20 or more years of residency had similar risks compared to non-Hispanic Whites. Conclusion: The “Hispanic Paradox” of better health despite lower socioeconomic status, was not observed in foreign-born or US-born Hispanics aged 65 years and older. Among elderly immigrants, those with fewer years of residency had the greatest hypertensive risk.


  • Platelet Component False Positive Detection Rate in Aerobic and Anaerobic Primary Culture: A Systematic Review and Meta-Analysis

    by Jessica Corean, Sandra K. White, Robert L. Schmidt, Brandon S. Walker, Mark A. Fisher, Ryan A. Metcalf


  • Cost‐effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant

    by Brandon S. Walker, Robert L. Schmidt, Srinivas Tantravahi, Kibum Kim, Kimberly E. Hanson

    Background: Invasive fungal infection (IFI) is a life‐threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) that is also associated with excess healthcare costs. Current approaches include universal antifungal prophylaxis, preemptive therapy based on biomarker surveillance, and empiric treatment initiated in response to clinical signs/symptoms. However, no study has directly compared the cost‐effectiveness of these treatment strategies for an allogeneic HSCT patient population.Methods: We developed a state transition model to study the impact of treatment strategies on outcomes associated with IFIs in the first 100 days following myeloablative allogeneic HSCT. We compared three treatment strategies: empiric voriconazole, preemptive voriconazole (200 mg), or prophylactic posaconazole (300 mg) for the management of IFIs. Preemptive treatment was guided by scheduled laboratory surveillance with galactomannan (GM) testing. Endpoints were cost and survival at 100 days post‐HSCT.Results: Empiric treatment was the least costly ($147 482) and was equally effective (85.2% survival at 100 days) as the preemptive treatment strategies. Preemptive treatments were slightly more costly than empiric treatment (GM cutoff ≥ 1.0 $147 910 and GM cutoff ≥ 0.5 $148 108). Preemptive therapy with GM cutoff ≥ 1.0 reduced anti‐mold therapy by 5% when compared to empiric therapy. Posaconazole prophylaxis was the most effective (86.6% survival at 100 days) and costly ($152 240) treatment strategy with a cost of $352 415 per life saved when compared to empiric therapy.Conclusions: One preemptive treatment strategy reduced overall anti‐mold drug exposure but did not reduce overall costs. Prevention of IFI using posaconazole prophylaxis was the most effective treatment strategy and may be cost‐effective, depending upon the willingness to pay per life saved.


  • Quality control limits: Are we setting them too wide?

    by Robert L. Schmidt, Brandon S. Walker, Lauren N. Pearson